Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Altorki

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The Oncologist|April 18, 2001
Early lung cancer action project: a summary of the findings on baseline screeningC I Henschke, D I McCauley, D F Yankelevitz, et al.
Cancer|July 10, 2001
Early lung cancer action project: initial findings on repeat screeningsC I Henschke, D P Naidich, D F Yankelevitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2023
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialE Felip, N Altorki, C Zhou, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The Oncologist|April 18, 2001
Early lung cancer action project: a summary of the findings on baseline screeningC I Henschke, D I McCauley, D F Yankelevitz, et al.
Cancer|July 10, 2001
Early lung cancer action project: initial findings on repeat screeningsC I Henschke, D P Naidich, D F Yankelevitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2023
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialE Felip, N Altorki, C Zhou, et al.
Pageof 3